Project Description

LipoCURE

At a glance

Established in 2009 by Prof. Yechezkel Barenholtz, Lipocure is a preclinical stage company developing novel liposomal drug candidates for post-surgical pain. LC400 is a novel liposomal hydrogel formulation of Bupivacaine for post-surgical pain. Lipocure’s drug candidates are based on liposomal chemistry that is characterized by the ability to improve pharmacological and pharmacokinetic profiles of known drugs as demonstrated in a large set of robust and comparative assessment system.

Company Highlights

Lipocure leverages on the vast experience and proven success of Prof. Barenholtz, a world leader in Liposome chemistry and therapeutics, including Doxil® that was then developed and commercialized by Johnson & Johnson.
As a platform technology, Lipocure has endless potential in its applications and the current pipeline represents products with very large commercial potential.

Key Shareholders

Integra Holdings, Prof. Barenholtz.

Funding

Extensive business development activity is ongoing to secure advancement into clinical development.

www.lipocure.com

More Companies